Study Complete
Sponsor ID
20040156

AIM 3: Anemia and Iron Management with every 3 week dosing in Anemic Subjects with Nonmyeloid Malignancies

Sponsor ID
20040156
Clinicaltrials.gov ID
NCT00135317
EUCTIS ID
N/A
EudraCT ID
N/A

Study Details

The study is designed to assess if the addition of intravenous (IV) iron to 500 mcg every 3 week (Q3W) darbepoetin alfa treatment enhances response as compared to the standard practice (oral iron or no iron administration).

Additional Study Details

Phase
Phase 3
Product
darbepoetin alfa
Type
Interventional
Masking
None (Open Label)
Enrollment
N/A
Additional Study Details

Protocol Summary

Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available

Study Documents

Study Synopsis
Available Language(s): English

Locations

No locations found.